Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene amplification in ductal carcinoma in situ of the breast.

Breast cancer research and treatment - 1 Oct 2010

Burkhardt L, Grob T J, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A

Abstract excerpt

Multiple different biologically and clinically relevant genes are often amplified in invasive breast cancer, including HER2, ESR1, CCND1, and MYC. So far, little is known about their role in tumor progression. To investigate their significance for tumor invasion, we compared pure ductal carcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Carcinoma, Intraductal, Noninfiltrating
Share to Cyclin D1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Lymphatic Metastasis

Share to Proto-Oncogene Proteins c-myc

Share to Receptor, ErbB-2

Share to Tissue Array Analysis

Source

Identifiers

PMID: 20033484
DOI: 10.1007/s10549-009-0675-8

Genes

CCND1
ESR1
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20033484-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene amplification in ductal carcinoma in situ of the breast.PMID 20033484Read ↗

FGFR1 is amplified during the progression of in situto invasive breast carcinomaSemantic proximity Read ↗

Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancerSemantic proximity Read ↗

Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.Semantic proximity Read ↗

Genomic Differences Between Pure Ductal Carcinoma In Situ of the Breast and that Associated with Invasive Disease: a Calibrated aCGH StudySemantic proximity Read ↗

Potential biomarkers of ductal carcinoma in situ progressionSemantic proximity Read ↗

Molecular Differences between Ductal Carcinoma<i>In Situ</i>and Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification StudySemantic proximity Read ↗

Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification studySemantic proximity Read ↗

Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.Semantic proximity Read ↗

C-myc oncogene amplification in ductal carcinoma in situ of the breast.Semantic proximity Read ↗

Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridizationSemantic proximity Read ↗

Detection of gene amplification in intraductal and infiltrating breast cancer by laser-assisted microdissection and quantitative real-time PCR.Semantic proximity Read ↗

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.